
DocGo (DCGO) Stock Forecast & Price Target
DocGo (DCGO) Analyst Ratings
Bulls say
DocGo is expected to experience strong revenue growth in the coming years, driven by the company's Mobile Health Services segment, particularly in the United States. The acquisition of SteadyMD enhances the company's virtual care capabilities and offers potential for higher margins. However, the company's path to profitability remains uncertain, and it will need to carefully manage operating expenses to achieve its target. While the current valuation may seem low, it is justified by the company's performance and outlook.
Bears say
DocGo is discontinuing coverage as the company has a history of underperforming their guidance and facing headwinds in their core medical transportation business. Despite some positive growth in key lines of business, there are concerns about the sustainability of revenue streams, including the potential for a decline in testing revenue after the COVID-19 pandemic. The company's recent SPAC merger and hesitancy from investors regarding the durability of their revenue stream have also contributed to a discounted valuation. Additionally, while guidance has been raised for the upcoming year, a modest EBITDA loss is still projected and there are concerns about the company's ability to scale their go-forward Mobile Health business and improve profitability. Overall, a "show me" stance is warranted at this time.
This aggregate rating is based on analysts' research of DocGo and is not a guaranteed prediction by Public.com or investment advice.
DocGo (DCGO) Analyst Forecast & Price Prediction
Start investing in DocGo (DCGO)
Order type
Buy in
Order amount
Est. shares
0 shares